TLSA vs. IMNM, AVBP, TRVI, PHAR, DAWN, DNTH, IOVA, ABUS, AKBA, and ZYBT
Should you be buying Tiziana Life Sciences stock or one of its competitors? The main competitors of Tiziana Life Sciences include Immunome (IMNM), ArriVent BioPharma (AVBP), Trevi Therapeutics (TRVI), Pharming Group (PHAR), Day One Biopharmaceuticals (DAWN), Dianthus Therapeutics (DNTH), Iovance Biotherapeutics (IOVA), Arbutus Biopharma (ABUS), Akebia Therapeutics (AKBA), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry.
Tiziana Life Sciences vs.
Immunome (NASDAQ:IMNM) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, community ranking, institutional ownership and dividends.
In the previous week, Immunome had 6 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 8 mentions for Immunome and 2 mentions for Tiziana Life Sciences. Immunome's average media sentiment score of 0.91 beat Tiziana Life Sciences' score of 0.50 indicating that Immunome is being referred to more favorably in the media.
Tiziana Life Sciences has a net margin of 0.00% compared to Immunome's net margin of -3,014.59%. Tiziana Life Sciences' return on equity of 0.00% beat Immunome's return on equity.
Tiziana Life Sciences received 57 more outperform votes than Immunome when rated by MarketBeat users. However, 78.00% of users gave Immunome an outperform vote while only 63.58% of users gave Tiziana Life Sciences an outperform vote.
Immunome has a beta of 2, suggesting that its stock price is 100% more volatile than the S&P 500. Comparatively, Tiziana Life Sciences has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500.
Immunome currently has a consensus price target of $23.33, indicating a potential upside of 194.61%. Given Immunome's stronger consensus rating and higher possible upside, equities research analysts clearly believe Immunome is more favorable than Tiziana Life Sciences.
44.6% of Immunome shares are owned by institutional investors. 8.6% of Immunome shares are owned by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Tiziana Life Sciences has lower revenue, but higher earnings than Immunome.
Summary
Immunome beats Tiziana Life Sciences on 9 of the 15 factors compared between the two stocks.
Get Tiziana Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tiziana Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:TLSA) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy TLSA Stock Free TLSA Stock Alerts